References
1. Rich TA, Schiller A, Suit HD, et al. Clinical and pathologic review of 48 cases of chordoma. Cancer . 1985;1;56(1):182–7. DOI: 10.1002/1097-0142(19850701)56:1<182::aid-cncr2820560131>3.0.co;2-j2. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes & Control . 2001;1;12(1):1–11. DOI: 10.1023/a:10089473017353. Zhou J, Sun J, Bai HX, et al. Prognostic Factors in Patients With Spinal Chordoma: An Integrative Analysis of 682 Patients. Neurosurgery . 2017;1;81(5):812–23. DOI: 10.1093/neuros/nyx0814. Chugh R, Tawbi H, Lucas DR, et al. Chordoma: the nonsarcoma primary bone tumor. The Oncologist . 2007;12(11):1344–50. DOI: 10.1634/theoncologist.12-11-13445. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: fifty years of experience.Spine . 2006;15;31(4):493–503. DOI: 10.1097/01.brs.0000200038.30869.276. Higinbotham NL, Phillips RF, Farr HW, et al. Chordoma. Thirty-five-year study at memorial hospital.Cancer . 1967;20(11):1841–50. DOI: 10.1002/1097-0142(196711)20:11<1841::aid-cncr2820201107>3.0.co;2-27. Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer . 1993;71(3):735–40. DOI: 10.1002/1097-0142(19930201)71:3<735::aid-cncr2820710314>3.0.co;2-88. Young VA, Curtis KM, Temple HT, et al. Characteristics and Patterns of Metastatic Disease from Chordoma. Sarcoma . 2015;2015:517657. DOI: 10.1155/2015/5176579. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol . 2006;209(2):157–65. DOI: 10.1002/path.196910. Ulici V, Hart J. Chordoma: A Review and Differential Diagnosis. Arch Pathol Lab Med . 2021;28;146(3):386–95. DOI: 10.5858/arpa.2020-0258-RA11. Niu XH. [Interpretation of 2020 NCCN Clinical Practice Guidelines in Oncology-Bone Cancer]. Zhonghua Wai Ke Za Zhi . 2020;58(6):430–4. DOI: 10.3760/cma.j.cn112139-20200204-0006112. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am . 2005;87(10):2211–6. DOI: 10.2106/JBJS.D.0269313. Ruggieri P, Angelini A, Ussia G, et al. Surgical margins and local control in resection of sacral chordomas.Clin Orthop . 2010;468(11):2939–47. DOI: 10.1007/s11999-010-1472-814. Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys . 1983;9(5):633–42. DOI: 10.1016/0360-3016(83)90228-615. Chen ATC, Hong CBC, Narazaki DK, et al. High dose image-guided, intensity modulated radiation therapy (IG-IMRT) for chordomas of the sacrum, mobile spine and skull base: preliminary outcomes. J Neurooncol . 2022;158(1):23–31. DOI: 10.1007/s11060-022-04003-w16. Ghaith AK, Nguyen R, El-Hajj VG, et al. Proton versus photon adjuvant radiotherapy: a multicenter comparative evaluation of recurrence following spinal chordoma resection. Neurosurg Focus . 2024;56(5):E9. DOI: 10.3171/2024.2.FOCUS2392717. Redmond KJ, Schaub SK, Lo S fu L, et al. Radiotherapy for Mobile Spine and Sacral Chordoma: A Critical Review and Practical Guide from the Spine Tumor Academy. Cancers . 2023;18;15(8):2359. DOI: 10.3390/cancers1508235918. Yeter HG, Kosemehmetoglu K, Soylemezoglu F. Poorly differentiated chordoma: review of 53 cases. APMIS . 2019;127(9):607–15. DOI: 10.1111/apm.1297819. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine.Cancer . 2000;88(9):2122–34. DOI: 10.1002/(sici)1097-0142(20000501)88:9<2122::aid-cncr19>3.0.co;2-120. Yang Y, Li Y, Liu W, et al. The clinical outcome of recurrent sacral chordoma with further surgical treatment. Medicine (Baltimore) . 2018;97(52):e13730. DOI: 10.1097/MD.000000000001373021. Meng T, Jin J, Jiang C, et al. Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review. Front Oncol . 2019;9:30. DOI: 10.3389/fonc.2019.0003022. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer . 2004;101(9):2086-97. doi: 10.1002/cncr.20618.23. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol . 2009;20(11):1886-94. DOI: 10.1093/annonc/mdp210.24. Peter J DeMaria, Marijo Bilusic, Deric M. Park, et. al. Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma, The Oncologist , 2021, 26(5):e847-e858. DOI: 10.1002/onco.1372025. Alexander AY, Dhawan S, Venteicher AS. Role of immunotherapy in treatment refractory chordomas: review of current evidence. Front Surg . 2024;30;11:1375567. DOI: 10.3389/fsurg.2024.1375567.